Physician profile
Burget Cort
NPI 1407463193
$685.37
in general payments reported to CMS, 2019-2025
17 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Registered Nurse provider received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $102 · 2023: $166 · 2024: $249 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $105.84 | 2024 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.96 | 2023 | Jardiance |
| Neurocrine Biosciences, INC. | $86.95 | 2023-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $66.78 | 2023-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $59.59 | 2022 | |
| Biogen, INC. | $46.01 | 2024 | Vumerity, Tysabri |
| Pfizer INC. | $37.06 | 2025 | |
| Axsome Therapeutics, INC. | $33.04 | 2024 | Sunosi |
| Otsuka America Pharmaceutical, INC. | $27.19 | 2023-2024 | Rexulti |
| Ucb, INC. | $20.58 | 2024 | Briviact |
| C2n Diagnostics, LLC | $15.46 | 2025 | Precivityad2 |
| Teva Pharmaceuticals USA, INC. | $15.14 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2022 | |
| Sk Life Science, INC. | $14.61 | 2022 | |
| Neurelis, INC. | $14.12 | 2025 | Valtoco |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $13.38 | 2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Burget Cort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.